Partners/Alliances

AD Summit: Rapid progress is being made in the diagnosis and treatment of Alzheimer's disease (AD).  New office-based techniques have simplified the detection of cognitive impairment and AD. Imaging techniques have advanced and now provide specific information on diagnosis of dementia and recognition of mild cognitive impairment in the earliest phases of AD. Magnetic resonance imaging, glucose positron emission technology, and amyloid imaging each make unique contributions to the diagnosis and characterization of dementia syndromes. Insight into the molecular pathology of AD has identified compounds with great therapeutic promise as well as new treatment targets. The optimal use of current AD therapies can substantially assist the patient in improving the symptoms or delaying the decline of function associated with the disease. Anti-amyloid and neuroprotective agents are currently in advanced stages of preclinical development.

The Alzheimer’s Disease Summit, to be held on May 3, 2008, will provide a comprehensive update of recent advances in AD diagnosis and management. Leading experts in the field, Jeffrey L. Cummings, MD, and Pierre N. Tariot, MD, will assemble an expert faculty that will cover a broad array of urgent topics in AD diagnosis and treatment. These key opinion leaders will give brief lectures focused on the principal clinically relevant questions surrounding their respective topics. There will be an opportunity for dialogue with each expert via question-and-answer sessions. A celebrity luncheon speaker will address the impact of AD on families. At the end of the day, a panel discussion will allow another opportunity for communication with the experts.

The panelists will be joined by a representative of the Food and Drug Administration who will provide an update on topics relevant to drug development and emerging therapies for AD. Participants will gain insight into how the FDA views important topics in drug development for AD.

Overall, participants will gain an improved understanding of how to recognize dementia, diagnose AD, and provide excellent treatment to AD patients and their families, as well as learn about the major areas of research where new treatment advances are anticipated.

To learn more and to register: www.adsummit2008.com.

MSSM: the Mount Sinai School of Medicine’s Office of Continuing Education is MBL’s official CME-accrediting body for development of accredited journal articles in both Primary Psychiatry and CNS Spectrums, as well as a variety of print and multimedia enduring material programs.

To learn more: www.mssm.edu/cme.

IADC: Beginning with the inaugural conference in February 2006, CNS Spectrums was selected as the Official Journal of the conference, as well as publishing partner of the International Anxiety Disorders Conference and will publish supplements stemming from conference proceedings.

i3CME: Effective mid-2005, MBL and i3CME entered into a strategic alliance to allow for the content of i3CME satellite broadcast programs to be to be extended to the combined audience of Primary Psychiatry and CNS Spectrums via Symposia Monograph Supplements and/or HyperCD programs.

To learn more: www.i3cme.com.

CINP: In January 2005, CNS Spectrums was approved by the Collegium Internationale Neuro-Psychopharmacologicum’s Executive Advisory Board for distribution to its members worldwide. The CINP is the largest international group of neuropsychopharmacologists with 1,200 members in 56 countries. In addition, in February 2006, MBL entered into a publishing agreement with the CINP for the association's 25th Biennial Congress to be held July 2006 in Chicago.

To learn more: www.cinp2006.com.

Summit Grey: Effective early 2004, MBL entered into a licensing agreement with SG for exclusive rights to develop, publish, and disseminate HyperCD technology in the CNS market through Primary Psychiatry and CNS Spectrums.

To learn more: www.summitgrey.com.

ADAA: In 2003, CNS Spectrums was selected by the Anxiety Disorders Association of America’s Medical Advisory Board to publish Enduring Materials from association congresses.

To learn more: www.adaa.org.